NCT04275245 is a Phase 1, PHASE2 clinical trial of Meplazumab for Injection in Coronavirus Disease 2019 (COVID-19), sponsored by Tang-Du Hospital.

Who is sponsoring NCT04275245?

NCT04275245 is sponsored by Tang-Du Hospital.

What drugs are being tested in NCT04275245?

Interventions in NCT04275245: Meplazumab for Injection.

What condition does NCT04275245 study?

NCT04275245 studies Coronavirus Disease 2019 (COVID-19).

Is NCT04275245 still recruiting?

NCT04275245 is currently completed. Last updated 9 April 2021.

Last reviewed 2021-04-09 · How we verify

NCT04275245

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia

Completed Phase 1, PHASE2 Last updated 9 April 2021

What this trial tests

Phase 1, PHASE2 trial testing Meplazumab for Injection in Coronavirus Disease 2019 (COVID-19) in 17 participants. Completed in 9 March 2020.

Timeline

3 February 2020

Primary endpoint
9 March 2020

9 March 2020

Quick facts

Lead sponsor	Tang-Du Hospital
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	17
Start date	3 February 2020
Primary completion	9 March 2020
Estimated completion	9 March 2020
Sites	1 location across China

Drugs / interventions tested

Meplazumab for Injection — full drug profile →

Conditions studied

Coronavirus Disease 2019 (COVID-19) — all drugs for Coronavirus Disease 2019 (COVID-19) →

Sponsor

Tang-Du Hospital

Who can join

Adults 18 to 75, any sex, with Coronavirus Disease 2019 (COVID-19). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the safety and efficacy of humanized Meplazumab for Injection in patients infected by 2019-nCoA.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts.
Wang J, Jiang M, Chen X, Montaner LJ. · · 2020 · cited 551× · PMID 32534467 · DOI 10.1002/jlb.3covr0520-272r
COVID-19: Transmission, prevention, and potential therapeutic opportunities.
Lotfi M, Hamblin MR, Rezaei N. · · 2020 · cited 447× · PMID 32474009 · DOI 10.1016/j.cca.2020.05.044
CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement.
Ulrich H, Pillat MM. · · 2020 · cited 291× · PMID 32307653 · DOI 10.1007/s12015-020-09976-7
Ongoing Clinical Trials for the Management of the COVID-19 Pandemic.
Lythgoe MP, Middleton P. · · 2020 · cited 247× · PMID 32291112 · DOI 10.1016/j.tips.2020.03.006
Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions.
Jafarzadeh A, Chauhan P, Saha B, Jafarzadeh S, et al · · 2020 · cited 246× · PMID 32687918 · DOI 10.1016/j.lfs.2020.118102
COVID-19 and Cancer: a Comprehensive Review.
Gosain R, Abdou Y, Singh A, Rana N, et al · · 2020 · cited 187× · PMID 32385672 · DOI 10.1007/s11912-020-00934-7
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, et al · · 2021 · cited 126× · PMID 34473343 · DOI 10.1002/14651858.cd013825.pub2

Verify or expand the search:

Other trials of Meplazumab for Injection

Trials testing the same drug.

NCT05113784 — the Safety and Efficacy of Meplazumab in Patients With COVID-19 · Phase 2, PHASE3 · completed
NCT04586153 — Study to Assess the Effect of Meplazumab on COVID-19 · Phase 2, PHASE3 · completed

Other recruiting trials for Coronavirus Disease 2019 (COVID-19)

Currently open trials in the same condition.

NCT06923137 — A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much · active not recruiting

Other Tang-Du Hospital trials

Trials by the same sponsor.

NCT07528235 — An Open-Label, Dose-Escalation Study on the Safety, Tolerability and Preliminary Efficacy for Preventing SAP by Intraven · Phase 1 · not yet recruiting
NCT07516522 — Intra-arterial Methylprednisolone After Endovascular Thrombectomy · Phase 2 · recruiting
NCT07354061 — Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC) · Phase 1, PHASE2 · recruiting
NCT07327736 — Anesthesia Comparison in Early-stage Small NSCLC: A Multicenter RCT · NA · not yet recruiting
NCT07452601 — Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04275245 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tang-Du Hospital
Last refreshed: 9 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04275245.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing